{
    "eid": "2-s2.0-84953369797",
    "title": "Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis",
    "cover-date": "2016-01-01",
    "subject-areas": [
        {
            "$": "General Neuroscience",
            "@code": "2800"
        },
        {
            "$": "Toxicology",
            "@code": "3005"
        }
    ],
    "keywords": [
        "Botulinum toxin",
        "Meta-analysis",
        "Neutralizing antibodies",
        "Systematic review"
    ],
    "authors": [
        "Margherita Fabbri"
    ],
    "citedby-count": 86,
    "ref-count": 33,
    "ref-list": [
        "EFNS guidelines on diagnosis and treatment of primary dystonias",
        "Basic immunological aspects of botulinum toxin therapy",
        "Regions of botulinum neurotoxin a light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. the antigenic structure of the active toxin recognized by human antibodies",
        "Clinical relevance of botulinum toxin immunogenicity",
        "Botulinum toxin therapy, immunologic resistance, and problems with available materials",
        "Parkinson\u2019s disease and movement disorders",
        "Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay",
        "Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: Report of 4 prospective, multicenter trials",
        "Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: A systematic review",
        "Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: The role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test",
        "Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial",
        "Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A",
        "Clinical presentation and management of antibody-induced failure of botulinum toxin therapy",
        "Immunological aspects of Botox\u00ae, Dysport\u00ae and Myobloc\u2122/ NeuroBloc\u00ae",
        "Botulinum a toxin therapy: Neutralizing and nonneutralizing antibodies - Therapeutic consequences",
        "Development of resistance to botulinum toxin type A in patients with torticollis",
        "Antitoxins and botulinum toxin treatment",
        "Mouse bioassay versus Western blot assay for botulinum toxin antibodies: Correlation with clinical response",
        "Therapy with botulinum toxin",
        "Clinical correlates of response to botulinum toxin injections",
        "Response and immunoresistance to botulinum toxin injections",
        "Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia",
        "Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia",
        "Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency",
        "Botulinum toxin type A neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: A multicenter, open-label clinical trial",
        "Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: Much ado about nothing?",
        "Long-term botulinum toxin efficacy, safety, and immunogenicity",
        "Optimisation of botulinum treatment for cervical and axial dystonias: Experience with a Japanese type A toxin",
        "A long-term follow-up of botulinum toxin a in cervical dystonia",
        "Immunogenicity of botulinum toxins",
        "Long-term efficacy and safety of botulinum toxin injections in dystonia",
        "Botulinum neurotoxin type A in urology: Antibodies as a cause of therapy failure",
        "Botulinum antibodies in dystonic patients treated with type A botulinum toxin: Frequency and significance"
    ],
    "affiliation": [
        {
            "affiliation-city": "Lisbon",
            "affilname": "Universidade de Lisboa",
            "affiliation-country": "Portugal"
        },
        {
            "affiliation-city": "Rome",
            "affilname": "Sapienza Universit\u00e0 di Roma",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Barcelona",
            "affilname": "Hospital Cl\u00ednic de Barcelona",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Los Angeles",
            "affilname": "David Geffen School of Medicine at UCLA",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulalongkorn University",
        "Ipsen"
    ]
}